![danaher beckman coulter danaher beckman coulter](https://assets.phenompeople.com/CareerConnectResources/prod/DANAGLOBAL/images/Tiffany-Murphy_inset-1588724400867.jpg)
Customers will benefit as the transaction will allow them to purchase all their testing needs from Beckman CoulterīREA, Calif., J/PRNewswire/ - Beckman Coulter, a global clinical diagnostics leader, today announced that it has entered into definitive agreements with Quidel Corporation to obtain all rights related to the manufacture, distribution, and sale of a BNP assay for Beckman Coulter analyzers. Laboratories will have continued supply of the high-quality BNP assay that exclusively runs on Beckman Coulter immunoassay platforms This BNP assay for Beckman Coulter immunoassay analyzers, currently sold as TRIAGE® BNP by Quidel, will now be sold by Beckman Coulter under the brand name Access BNP Additional information regarding theįactors that may cause actual results to differ materially from these forward-looking statements is available in Danahers SEC filings, including Danahers Annual Report on Form 10-K for the year ended December 31, 2010.- Beckman Coulter to take over distribution to customers of a B-type Natriuretic Peptide (BNP) assay, a marker of congestive heart failure on the company's immunoassay platforms These factors include risks and uncertainties related to, among other things: general economic conditions and conditions affecting the industries in which Danaher and BeckmanĬoulter operate the parties ability to satisfy the merger agreement conditions and consummate the transaction and Beckman Coulters performance and maintenance of important business relationships. Should not place undue reliance on any such forward-looking statements. There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements and you Of the federal securities laws, and involve a number of risks and uncertainties. Including statements regarding completion of the transaction, and any other statements regarding events or developments that we believe or anticipate will or may occur in the future, may be forward-looking statements within the meaning Statements in this release that are not strictly historical, For more information please visit Danahers website: Forward Looking Statements Driven by a foundation provided by the Danaher Business System, Danahers 48,000Īssociates serve customers in more than 125 countries and generated $12.8 billion of revenue in 2010. Its portfolio of premier brands is among the most highly recognized in each of the markets it serves. Professional, medical, industrial, and commercial customers. Danaher continues to anticipate that the transaction will close in June 2011.ĭanaher Corporation is a diversified technology leader that designs, manufactures, and markets innovative products and services to York City time, on Friday, June 24, 2011. The offer is scheduled to expire at 5:00 p.m., New The ∺ntitrust Condition to the offer has now been satisfied. This was the last applicable regulatory approval with respect to Danahers previously announced tender offer to acquire all of the outstanding shares of Beckman Coulter for $83.50 per
![danaher beckman coulter danaher beckman coulter](https://media.glassdoor.com/template/l/87/beckman-coulter-template-1608768592752.jpg)
J Danaher Corporation (NYSE:DHR) announced today that approval from the European Commission had been received forĭanahers proposed acquisition of Beckman Coulter. Exhibit (a)(5)(H) Press Release issued by Danaher Corporationĭanaher Obtains European Commission Approval to Acquire Beckman Coulter